| Literature DB >> 33585238 |
Alejandro Mazal1, Juan Antonio Vera Sanchez1, Daniel Sanchez-Parcerisa2,3,4, Jose Manuel Udias2,3, Samuel España2,3, Victor Sanchez-Tembleque2,3, Luis Mario Fraile2,3, Paloma Bragado3,5, Alvaro Gutierrez-Uzquiza3,5, Nuria Gordillo6,7, Gaston Garcia7, Juan Castro Novais1, Juan Maria Perez Moreno1, Lina Mayorga Ortiz1, Amaia Ilundain Idoate1, Marta Cremades Sendino1, Carme Ares1, Raymond Miralbell1, Niek Schreuder8.
Abstract
Proton therapy has advantages and pitfalls comparing with photon therapy in radiation therapy. Among the limitations of protons in clinical practice we can selectively mention: uncertainties in range, lateral penumbra, deposition of higher LET outside the target, entrance dose, dose in the beam path, dose constraints in critical organs close to the target volume, organ movements and cost. In this review, we combine proposals under study to mitigate those pitfalls by using individually or in combination: (a) biological approaches of beam management in time (very high dose rate "FLASH" irradiations in the order of 100 Gy/s) and (b) modulation in space (a combination of mini-beams of millimetric extent), together with mechanical approaches such as (c) rotational techniques (optimized in partial arcs) and, in an effort to reduce cost, (d) gantry-less delivery systems. In some cases, these proposals are synergic (e.g., FLASH and minibeams), in others they are hardly compatible (mini-beam and rotation). Fixed lines have been used in pioneer centers, or for specific indications (ophthalmic, radiosurgery,…), they logically evolved to isocentric gantries. The present proposals to produce fixed lines are somewhat controversial. Rotational techniques, minibeams and FLASH in proton therapy are making their way, with an increasing degree of complexity in these three approaches, but with a high interest in the basic science and clinical communities. All of them must be proven in clinical applications.Entities:
Keywords: FLASH; arc therapy; gantry; minibeams; proton therapy
Year: 2021 PMID: 33585238 PMCID: PMC7874206 DOI: 10.3389/fonc.2020.613669
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244